Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Contineum Therapeutics (CTNM) Other Non-Current Liabilities: 2023-2024

  • Contineum Therapeutics' Other Non-Current Liabilities was N/A to $228,000 in Q1 2024 from the same period last year, while for Mar 2024 it was $228,000, marking a year-over-year change of. This contributed to the annual value of $110,000 for FY2023, which is N/A change from last year.
  • Latest data reveals that Contineum Therapeutics reported Other Non-Current Liabilities of $228,000 as of Q1 2024, which was up 107.27% from $110,000 recorded in Q4 2023.
  • In the past 5 years, Contineum Therapeutics' Other Non-Current Liabilities registered a high of $228,000 during Q1 2024, and its lowest value of $110,000 during Q4 2023.
  • Over the past 2 years, Contineum Therapeutics' median Other Non-Current Liabilities value was $169,000 (recorded in 2023), while the average stood at $169,000.